101 related articles for article (PubMed ID: 7856614)
1. Cost-effective use of cytomegalovirus immune globulin in recipients of orthotopic liver transplants.
Uber LA
Am J Hosp Pharm; 1994 Nov; 51(22):2843, 2846. PubMed ID: 7856614
[No Abstract] [Full Text] [Related]
2. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
[TBL] [Abstract][Full Text] [Related]
3. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group.
Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD; O'Rourke E
Transplant Proc; 1994 Oct; 26(5 Suppl 1):23-7. PubMed ID: 7940972
[No Abstract] [Full Text] [Related]
4. Incidence of cytomegalovirus infection and effects of cytomegalovirus immune globulin prophylaxis after orthotopic liver transplantation.
Saliba F; Gugenheim J; Samuel D; Bismuth A; Mathieu D; Serres C; Bismuth H
Transplant Proc; 1987 Oct; 19(5):4081-2. PubMed ID: 2823435
[No Abstract] [Full Text] [Related]
5. Elimination of cytomegalovirus disease in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir.
Prian GW; Koep LJ
Transplant Proc; 1994 Oct; 26(5 Suppl 1):54-5. PubMed ID: 7940977
[No Abstract] [Full Text] [Related]
6. A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial.
Snydman DR; Werner BG; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS; Strom TB; Carpenter CB
Transplant Proc; 1988 Dec; 20(6 Suppl 8):24-30. PubMed ID: 2849222
[No Abstract] [Full Text] [Related]
7. Prevention of cytomegalovirus infection in bone marrow transplant recipients by prophylaxis with an intravenous, hyperimmune cytomegalovirus globulin.
Condie RM; O'Reilly RJ
Birth Defects Orig Artic Ser; 1984; 20(1):327-44. PubMed ID: 6329370
[No Abstract] [Full Text] [Related]
8. Cytomegalovirus infection in bone marrow transplant recipients: use of intravenous gamma globulin as a prophylactic and therapeutic agent.
Kapoor N; Copelan EA; Tutschka PJ
Transplant Proc; 1989 Feb; 21(1 Pt 3):3095-6. PubMed ID: 2539686
[No Abstract] [Full Text] [Related]
9. Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation.
Basadonna G; Feria A; Perez R; Klein H; Sturges M; Colquhoun S
Transplant Proc; 1994 Oct; 26(5 Suppl 1):52-3. PubMed ID: 7940976
[No Abstract] [Full Text] [Related]
10. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus immune globulin in renal-transplant recipients.
N Engl J Med; 1988 Apr; 318(16):1065-7. PubMed ID: 2832759
[No Abstract] [Full Text] [Related]
12. Use of ganciclovir plus cytomegalovirus immune globulin to treat CMV pneumonia in orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG-Study Group.
George MJ; Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD
Transplant Proc; 1993 Oct; 25(5 Suppl 4):22-4. PubMed ID: 8212303
[No Abstract] [Full Text] [Related]
13. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
[TBL] [Abstract][Full Text] [Related]
14. CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study.
Saliba F; Arulnaden JL; Gugenheim J; Serves C; Samuel D; Bismuth A; Mathieu D; Bismuth H
Transplant Proc; 1989 Feb; 21(1 Pt 2):2260-2. PubMed ID: 2540564
[No Abstract] [Full Text] [Related]
15. Aciclovir or ganciclovir universal prophylaxis of cytomegalovirus infection in liver transplantation: an economic analysis.
Leong RW; Smith DW; Garas G; Beaman JM; Mitchell AW; Heath DI; House AK; Jeffrey GP
Intern Med J; 2004 Jul; 34(7):410-5. PubMed ID: 15271175
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus infections in the immunocompromised transplant patient. Prevention of cytomegalovirus disease with intravenous immune globulin.
Snydman DR
Transplant Proc; 1991 Apr; 23(2 Suppl 1):20-5. PubMed ID: 1647560
[No Abstract] [Full Text] [Related]
17. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
[TBL] [Abstract][Full Text] [Related]
18. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients--a meta-analysis.
Glowacki LS; Smaill FM
Clin Transplant; 1994 Feb; 8(1):10-8. PubMed ID: 8136560
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients.
Das A
Hepatology; 2000 Feb; 31(2):311-7. PubMed ID: 10655251
[TBL] [Abstract][Full Text] [Related]
20. Prevention of cytomegalovirus disease in transplant recipients.
Pidgeon GB; Bailey RR
N Z Med J; 1993 Nov; 106(967):468-9. PubMed ID: 8233192
[No Abstract] [Full Text] [Related]
[Next] [New Search]
